| Up
2005P-0007:
ANDA SUITABILITY FOR RISPERIDONE ORALLY DISINTEGRATING TABLETS,
0.25 MG
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Document #
|
| Received Date
|
| Filed
Date
|
| Submitter Code
|
| Submitter
|
| FR
Date
|
| FR
Page
|
| Comment Date
|
| Files
|
| Remarks
|
|
|
|
|
|
|
| CP1
|
| 01/05/2005
|
| 01/05/2005
|
| Private Industry
|
| Lachman Consultant
Services, Inc.
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
| Signature:
|
| Robert W. Pollock
|
|
|
|
|
| ACK1
|
| 01/05/2005
|
| 01/05/2005
|
| Federal Government
|
| HFA-305 to Lachman
Consultant Services, Inc.
|
|
|
|
|
|
|
| pdf,
Attachments: 01,
03
|
|
|
|
|
|
|
| Signature:
|
| Lyle D. Jaffe
|
|
|
|
|
| PAV1
|
| 04/01/2005
|
| 04/01/2005
|
| Federal Government
|
| HFD-600 to Lachman
Consultant Services, Inc.
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
|
|
| Signature:
|
| Gary J. Buehler
|
|
|
|
| |
Top | Up
Page last updated
May 11, 2005
kk |
